Next Generation Sequencing Market Size & Growth Report

The global next-generation sequencing (NGS) market is poised for substantial growth, driven by technological advancements, increased government funding, and the expanding application of genomic data in healthcare. Valued at USD 11.06 billion in 2024, the market is expected to expand at a remarkable CAGR of 14.90% during the forecast period of 2025-2034, reaching an estimated value of USD 44.36 billion by 2034. This blog post explores the market's overview, size, growth factors, trends, segmentation, and the key players contributing to its rapid expansion.

Next Generation Sequencing Market Overview

Next-generation sequencing (NGS) refers to a high-throughput method used to sequence DNA and RNA, enabling rapid and accurate genomic analysis. NGS technologies allow for large-scale sequencing projects, such as the Human Genome Project, and are used for applications ranging from personalized medicine to disease diagnostics. NGS provides numerous advantages, including greater accuracy, speed, and cost-effectiveness compared to traditional sequencing methods. The growing demand for genetic data to drive healthcare innovations, such as targeted therapies and personalized treatments, is fueling the adoption of NGS platforms worldwide.

Next Generation Sequencing Market Size

The global next-generation sequencing market was valued at approximately USD 11.06 billion in 2024. This reflects the increasing demand for NGS technologies across various industries, including healthcare, research, and diagnostics. Over the forecast period of 2025-2034, the market is expected to grow at a compound annual growth rate (CAGR) of 14.90%, driven by advancements in sequencing technologies, the availability of government funding, and the rising demand for large-scale genome projects. By 2034, the market is projected to reach a value of about USD 44.36 billion, marking a significant expansion from its current size.

Next Generation Sequencing Market Share

The NGS market is highly competitive, with several key players holding significant shares across different regions and segments. Illumina Inc. is a dominant player in the NGS market, offering a broad range of sequencing systems and services. Other major companies, such as Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., and Bio-Rad Laboratories, also contribute significantly to the market share. These companies have established strong market positions due to their advanced NGS technologies, innovative products, and widespread distribution networks. Additionally, startups and niche players focused on specialized NGS applications and platforms are increasingly capturing market share as demand for personalized genomic testing grows.

Next Generation Sequencing Market Trends

Several key trends are driving the evolution of the NGS market:

Rise in Personalized Medicine: NGS is increasingly being used to identify genetic variations that can be targeted by specific therapies, making personalized medicine one of the most important drivers of market growth.
Technological Advancements: Continuous improvements in NGS technology are driving the market. For instance, the development of single-cell sequencing, long-read sequencing, and improvements in data analysis algorithms are increasing the accuracy and reducing the cost of NGS.
Government Funding: Many governments around the world are investing heavily in genomics and biotechnology research, funding large-scale genome projects that rely on NGS technology to map genomes and explore gene functions.
Growing Application in Oncology: NGS is being increasingly used for cancer diagnostics and to understand genetic mutations driving various types of cancers. Liquid biopsy technologies, which rely on NGS, are becoming more widely adopted in oncology.
Integration with Artificial Intelligence (AI): AI and machine learning are being integrated with NGS platforms to enhance data analysis, offering deeper insights into complex genomic data.

Next Generation Sequencing Market Analysis

The global NGS market is experiencing significant growth, primarily due to advancements in sequencing technology, increased government and private sector funding, and the growing importance of genomics in medical research. The reduction in the cost of sequencing, coupled with an increasing number of research projects in genomics, has made NGS more accessible for clinical applications.

NGS technologies have enabled the sequencing of large genomes at lower costs, driving innovations in fields like genomics, oncology, and reproductive medicine. The increasing prevalence of genetic disorders, the need for early detection of diseases, and the focus on personalized medicine are other major growth drivers for the NGS market. Additionally, NGS is gaining traction in non-clinical applications such as agricultural biotechnology, microbial analysis, and environmental science.

However, challenges such as data interpretation, the need for standardization, and privacy concerns related to genetic data pose some risks to the market's growth. Despite these challenges, NGS remains a highly promising field with vast potential for the future.

Next Generation Sequencing Market Segmentation

The NGS market is divided into several segments based on technology, application, end-user, and region. Below are the key segments:

Technology

Sequencing by Synthesis (SBS): This is the most widely used NGS technology, employed by major platforms like Illumina’s sequencing systems.
Ion Semiconductor Sequencing: This technology offers faster sequencing and is used in platforms such as Thermo Fisher’s Ion Proton.
Single-Molecule Real-Time (SMRT) Sequencing: SMRT sequencing is used for long-read sequencing and is offered by platforms such as Pacific Biosciences’ Sequel System.
Nanopore Sequencing: This newer technology offers real-time, long-read sequencing, and is used by Oxford Nanopore Technologies.

Application

Oncology: The application of NGS in oncology is expanding rapidly due to its ability to detect genetic mutations and guide personalized cancer therapies.
Reproductive Health: NGS is being used for non-invasive prenatal testing, genetic screening, and fertility diagnostics.
Genomic Research: NGS is fundamental to research in genomics, enabling large-scale sequencing projects such as the Human Genome Project.
Infectious Disease: NGS is used to sequence microbial genomes, including viruses and bacteria, to understand the spread of infectious diseases.

End-User

Research Institutes: Academic and government research institutes are major users of NGS technology, conducting large-scale genome studies and clinical trials.
Hospitals & Clinics: NGS is increasingly used in clinical settings for diagnostics, particularly for genetic disorders and oncology applications.
Pharmaceutical & Biotech Companies: These companies leverage NGS for drug discovery and development, personalized medicine, and clinical trials.

Region

North America: North America is expected to maintain its dominance in the NGS market, driven by technological advancements, strong healthcare infrastructure, and high investment in research.
Europe: Europe follows closely behind, with governments and healthcare systems increasingly investing in genomic research and personalized medicine.
Asia-Pacific: The Asia-Pacific region is poised for rapid growth due to increasing healthcare investments, expanding research initiatives, and increasing adoption of NGS technologies in China and India.
Rest of the World: Latin America, the Middle East, and Africa are showing steady growth, driven by government investments in healthcare and research.

Next Generation Sequencing Market Growth

The global next-generation sequencing market is expected to grow significantly at a CAGR of 14.90% between 2025 and 2034, owing to the continuous advancements in sequencing technologies, the growing demand for personalized medicine, and increased funding for large-scale genome projects. As healthcare providers increasingly recognize the value of genomics, the adoption of NGS is expected to rise across research institutions, hospitals, and clinical laboratories. The market's growth is further supported by the rising prevalence of genetic disorders, cancer, and infectious diseases, as well as increasing awareness about the potential of genomics in personalized healthcare.

Recent Developments and Challenges in the Next Generation Sequencing Market

Recent developments in the NGS market include significant advancements in sequencing technologies, such as long-read sequencing and single-cell sequencing, which offer greater resolution and can be used for a wider range of applications. Companies like Illumina and Thermo Fisher Scientific have continued to innovate, releasing more advanced sequencing systems that reduce costs and increase throughput.

However, challenges remain, including high data analysis costs, the complexity of genomic data interpretation, and the need for more standardized protocols across platforms. Regulatory hurdles for clinical applications and concerns over data privacy and security also pose challenges to market growth.

Get a Free Sample Report with a Table of Contents

Key Players in the Next Generation Sequencing Market

Several companies dominate the NGS market, including:

Illumina Inc.

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

Bio-Rad Laboratories, Inc.

PierianDx

Genomatrix GmbH

DNASTAR, Inc.

Perkin Elmer, Inc.

Eurofins GATC Biotech GmbH

Agilent Technologies, Inc.

Danaher Corp.

BGI Genomics